Answers are grounded in this paper and cite their sources.
Sir: In benign breast procedures, excess breast tissue is resected to alleviate physical and psychological distress. The clinical indications for these procedures vary greatly depending on the gender of the patient seeking treatment. Reduction mammaplasty is indicated for the treatment of macromastia in cisgender women (female gender identity, assigned female at birth). Gynecomastia surgery is offered for the treatment of gynecomastia in cisgender men (male gender identity, assigned male at birth). Gender-affirming mastectomy is one intervention used to address gender dysphoria in transgender men (male gender identity, assigned female at birth). Significant improvements in quality of life have been attributed to all three procedures.1–3 Insurance coverage for these procedures has been shown to be highly variable, despite their clear therapeutic effect.4,5 However, to date, no study has compared how individual policies differentiate coverage for these three procedures. Our study examined how the gender of a patient impacts the way in which the medical necessity of breast surgery is conceptualized. We reviewed the policies of 20 health insurance providers to compare coverage criteria. For each procedure, we examined the criteria from the websites of the nine largest national insurance networks that have national coverage guidelines, the six federal plans available through the Federal Employees Health Benefits plan, and five state plans for a large national network with state-based coverage policies. Standard coverage criteria for each procedure were identified and their adoption was recorded for each provider (Table 1). Descriptive statistics were calculated.Table 1.: Insurance Coverage Requirements for Reduction Mammaplasty, Gynecomastia Surgery, and Gender-Affirming Mastectomy Listed by ProviderThere were clear coverage inconsistencies with regard to breast surgery between different groups based on assigned sex and gender identity. All of the policies examined were willing to cover reduction mammaplasty, although requirements varied. Six of 20 plans categorically refused to cover gynecomastia surgery (two national networks, two federal plans, and two state plans). Two of 20 plans, both federal, excluded gender-affirming mastectomy. Plans that did cover each procedure also had different requirements for accessing them. Half (10 of 20) of the policies covering reduction mammaplasty explicitly required patients to be older than 18 years, compared to five of 14 gynecomastia surgery policies and 16 of 18 gender-affirming mastectomy policies. “Trial periods,” involving conservative treatment (reduction mammaplasty and gynecomastia surgery) or time lived in the affirmed gender (gender-affirming mastectomy), were required by 19 of 20 reduction mammaplasty policies, nine of 14 gynecomastia surgery policies, and five of 18 gender-affirming mastectomy policies. Length of trial period also varied by type of surgery. Gender-affirming mastectomy policies required the longest trial periods (minimum, 1 year), with shorter periods required by gynecomastia surgery (6 to 12 months) and reduction mammaplasty (6 weeks to 6 months) policies. In addition, two of 18 gender-affirming mastectomy policies required a legal name change before transition. There is no equivalent policy for gynecomastia surgery and reduction mammaplasty patients. Overall, gender-affirming mastectomy was the procedure with the most variably adopted criteria. There were eight different combinations of four selected criteria observed across provider policies. This was in comparison to five combinations of four criteria for reduction mammaplasty and four combinations of four criteria for gynecomastia surgery. In summary, insurance coverage and access regulation for benign breast procedures are highly variable both across insurers and between procedures. Although reduction mammaplasty, gynecomastia surgery, and gender-affirming mastectomy have similar purposes (i.e., to relieve psychological and/or physical distress caused by excess breast tissue) and use similar techniques, the ways in which coverage varies suggests that patient assigned sex and/or gender identity may play a role in policy formation. Improving the consistency of insurance coverage, and standardizing coverage criteria for procedures involving breast tissue excision, would have the potential to ensure more equitable access and streamline the process of care. DISCLOSURE The authors have no conflicts of interest to disclose. Anthony N. AlmazanHarvard Medical School Elizabeth R. Boskey, Ph.D., M.P.H., L.I.C.S.W.Boston Children’s HospitalCenter for Gender Surgery Brian Labow, M.D.Department of Plastic and Oral SurgeryBoston Children’s Hospital Oren Ganor, M.D.Center for Gender SurgeryBoston Children’s HospitalBoston, Mass.
No takes yet. Share an insight, caveat, or question.
Almazan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: